Cognition Therapeutics (NASDAQ:CGTX) Given “Buy” Rating at Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They presently have a $11.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.20.

Cognition Therapeutics Trading Up 27.5 %

NASDAQ:CGTX opened at $0.58 on Thursday. The company’s 50 day moving average is $0.47 and its two-hundred day moving average is $0.94. The company has a market cap of $24.10 million, a PE ratio of -0.60 and a beta of 1.26. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics in the 3rd quarter valued at about $27,000. Sigma Planning Corp lifted its stake in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares in the last quarter. Finally, CM Management LLC grew its position in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after buying an additional 25,000 shares during the period. 43.35% of the stock is owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.